FORESIGHT is transforming drug development by using advanced molecular imaging to track medicines in the body and identify the best treatment for each patient. This innovative approach makes drug development faster, more effective, and more personalized, helping to bring better treatments to those who need them most.
Improving drug development and choices with molecular imaging
FORESIGHT: A Public-Private Partnership for Drug Development
The FORESIGHT Service and Innovation Center and Program bring together the expertise and infrastructure of UMCG, AUMC, NKI/AVL, and TU/e, in collaboration with (inter)national partners. By combining strengths in tracer development, bioengineering, imaging, and AI-driven data analysis, FORESIGHT aims to transform drug development and precision medicine.
The Urgent Need for Innovation in Healthcare
Chronic and severe diseases pose an increasing burden on society. The number of patients is expected to rise sharply, overwhelming healthcare systems and driving costs to unsustainable levels. Despite the urgent need for new treatments, drug development remains highly inefficient—taking an average of 10 years and costing at least €1 billion per drug, with a high failure rate. Even among approved medicines, 90% do not work for all patients. Additionally, diagnostic imaging—which could help predict drug efficacy and personalize treatments—is rarely used in development or clinical practice.
Transforming Drug Development with Advanced Imaging
FORESIGHT addresses these challenges by applying molecular nuclear and optical imaging to develop imaging biomarkers—providing tools for cell-level tissue mapping till real-time drug tracking in the body. These innovations will:
Improve early-stage (preclinical) testing, reducing failure rates
This is achieved by identifying the right patients for specific treatments and increasing drug effectiveness, optimizing clinical trial design, making development faster and more cost-effective. By integrating these technologies, FORESIGHT enhances precision medicine, ensuring patients receive the most effective treatments.
Deliverables and Impact
The FORESIGHT-PPS program will deliver: Cutting-edge imaging solutions for drug assessment. Collaborative R&D projects with industry partners. Preclinical and clinical imaging studies for major diseases. AI-powered data analysis to improve healthcare decision-making.
Parties that can participate
People will be invited to participate through an open call, information regarding submission of projects will be provided on the FORESIGHT website and connections can be made via a special FORESIGHT email address.
Through these innovations, FORESIGHT will demonstrate the power of molecular imaging, driving long-term growth in precision medicine.